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Results:
Median follow-up time was 20 months (range, 9-55 months) . Median lesion size was 20 mm (range, 8-50 mm) . Due to statistical evaluations around the median range of SUV (max), a pre SABR SUV (max) 5.0 was selected as a cut-off to analyze LC and OS. The 2-year LC was 61.2% versus 78.7% for higher or equal than 5.0 versus lower than 5.0 SUV (max), yielding an adjusted sub-hazard ratio (SHR) for high pre SABR SUV (max) of 5.3 (95% confidence interval [CI], 1.3-25.5; p = 0.057). Two-year OS was 80.6% versus 76.6% respectively (hazard ratio [HR], 1.4; 95%; p = 0.46). No differences were observed between fractionation schedules or different tumor volumes.
Conclusion: FDG uptake (SUV (max) ≥5.0) before SABR signifies reduces risk of local failure. These results from single institution might stimulate a large accrual from multicenter prospective analysis, due to controversial results already published. Purpose or Objective: To report our initial experience in stereotactic body radiation therapy (SBRT) delivered using RapidArc (RA) technique with or without flattening filter beam in terms of toxicity and clinical outcomes.
Material and Methods:
From September 2013 to September 2015, 16 consecutive patients with 27 metastatic hepatic lesions were treated with SBRT in a TrueBeam unit using RA technique. 6 lesions received a Volumetric Modulated Arc Therapy (VMAT) treatment using 6Mv RA with flattening filter and 21 were treated without flattening filter (flattening filter free beam-FFF) with an energy of 10Mv. GTV was defined using multi-phase CT scans, PET/CT and/or MRI. The lesions were marked with a radiopaque coil to localize them in the verification CBCT (ConeBeamCT) that was performed daily. ITV (internal target volume) was calculated in gated modality with internal coil tracking by 2D imaging. Prescribed doses ranged from 30-60Gy in 3-5 fractions to ITV. The dose was downscaled in cases of not full achievement of dose constraints. 99.5% of the target volume was covered by 100% of the prescription dose. Initially, we followed the constraints proposed by Timmerman: Three fractions constraints for organs at risk were: 700cc of liver free from the 17.1Gy isodose, Dmax< 24Gy for stomach and duodenum, D5cc< 15Gy for duodenum, Dmax< 30Gy for heart, D1.2cc< 11Gy and D0.25Gy< 18Gy for spinal cord. Five fractions constraints for organs at risk were: 700cc of liver free from the 21Gy isodose, Dmax< 32Gy for stomach and duodenum, D5cc< 18Gy for duodenum, Dmax< 38Gy for heart, D1.2cc< 13.5Gy and D0.25Gy< 22.5Gy for spinal cord. Nowadays we are following the constraints proposed by the Spanish Society of Radiation Oncology: Liver: 700cc of liver free from the 15Gy isodose, V21<30%, V15<20Gy, Mean dose: <15Gy for three fractions and <20Gy for five fractions; D5cc<15Gy for duodenum; V30<1cc and V21<5cc for heart; Dmax<18Gy for spinal cord.
Results: Mean age of the patients was 59 years and the mean following time since the end of SBRT was 9.14 months. ITV mean volume was 41.78cc. The most frequent side effect was acute asthenia and we identified two cases of asymptomatic increase in liver enzymes. No patient experienced acute toxicity greater than Grade 2. In relation to the local response, we used RECIST and/or PERCIST criteria to reevaluate the lesions. We found 15 complete and 1 partial responses, 1 progression, 5 stable lesions and 2 pseudo progressions. 2 patients (4 lesions) were lost in the long-term clinical follow up. No differences between both treatment modalities (with or without FF) were found in terms of local control or side effects (either acute or chronic).
Conclusion:
SBRT for liver targets delivered by means of RapidArc resulted to be a feasible technique, with few side effects and good rates of local response in metastatic liver targets. 
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